Ann: PharmAust Presentation, page-68

We need to move on from missed opportunities. Focus on where we are today. I'm glad they didn't raise $20 million. That would have been overly dilutive. By the time we get an outcome there will probably be 600 million SOI. That's pretty good compared to peers. PAA is in a very good position with a promising drug emerging just when other treatments fail or underperform. It's a big category, neurodegenerative disease. The FDA has been generous in its treatment of our applications. ODD granted and preliminary approval considered. We may only be a year away from 24 week results. So Buckland while I like the negative balance you bring to this forum, I have to disagree with your outlook.